Skip to main content
. 2023 Feb 22;15(5):1395. doi: 10.3390/cancers15051395

Figure 2.

Figure 2

Overview of National Comprehensive Cancer Network (NCCN)-recommended targeted agents. HGF: hepatocyte growth factor; c-MET: mesenchymal–epithelial transition factor; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; EGFR: epidermal growth factor receptor; EGF: epidermal growth factor; HER2: human epidermal growth factor 2; CTLA-4: cytotoxic T lymphocyte-associated antigen 4; PD-1: programmed death-1; PD-L1: programmed death ligand 1; PI3K: phosphoinositide 3-kinase; AKT: protein kinase B, also known as PKB; mTOR: mammalian target of rapamycin; MEK: mitogen-activated protein kinase; ERK: extracellular signal regulated kinase. * These agents have not been recommended by the NCCN. ** This agent has been approved by the National Medical Products Administration of China (NMPA), but not by the United States of America Food and Drug Administration (FDA) [15].